US Patent

US8648106 — Dexmedetomidine premix formulation

Formulation · Assigned to Hospira Inc · Expires 2032-01-04 · 6y remaining

Vulnerability score 36/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a premixed liquid formulation of dexmedetomidine hydrochloride for parenteral administration.

USPTO Abstract

The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.

Drugs covered by this patent

Patent Metadata

Patent number
US8648106
Jurisdiction
US
Classification
Formulation
Expires
2032-01-04
Drug substance claim
No
Drug product claim
Yes
Assignee
Hospira Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.